{"id":48857,"date":"2025-11-24T20:00:21","date_gmt":"2025-11-24T12:00:21","guid":{"rendered":"https:\/\/flcube.com\/?p=48857"},"modified":"2025-11-24T20:00:22","modified_gmt":"2025-11-24T12:00:22","slug":"biokins-iza-bren-nda-accepted-for-nasopharyngeal-carcinoma-advancing-bispecific-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48857","title":{"rendered":"Biokin&#8217;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC"},"content":{"rendered":"\n<p><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that its New Drug Application (NDA) for <strong>iza-bren<\/strong> (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class <strong>EGFR\u00d7HER3 bispecific ADC<\/strong>, has been formally accepted by the <strong>National Medical Products Administration (NMPA)<\/strong> for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\/PD\u2011L1 therapy and at least two chemotherapy lines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>iza\u2011bren (BL\u2011B01D1)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Sichuan Biokin Pharmaceutical (688506.SH)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>New Drug Application (NDA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Recurrent\/metastatic NPC post PD\u20111\/PD\u2011L1 + \u22652 chemo lines (\u22651 platinum)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Formally accepted for review<\/td><\/tr><tr><td><strong>Global Position<\/strong><\/td><td>Only EGFR\u00d7HER3 bispecific ADC in Phase\u202fIII globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development\">Drug Profile &amp; Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> First\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC delivering cytotoxic payload to dual\u2011target tumor cells<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> <strong>>40 clinical trials<\/strong> ongoing in China and U.S. across multiple tumor types<\/li>\n\n\n\n<li><strong>Breakthrough Designations:<\/strong> <strong>7 indications<\/strong> on CDE BTD list (China); <strong>1 indication<\/strong> on FDA BTD list (U.S.)<\/li>\n\n\n\n<li><strong>Global Partnership:<\/strong> In December\u202f2023, <strong>Bristol Myers Squibb<\/strong> acquired ex\u2011China rights for iza\u2011bren, providing <strong>$800\u202fmillion upfront<\/strong> plus milestones<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China NPC Incidence<\/strong><\/td><td>~120,000 new cases annually<\/td><\/tr><tr><td><strong>Recurrent\/Metastatic Population<\/strong><\/td><td>~30% of patients (36,000 cases)<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Chemotherapy; no approved ADCs for HER3\u2011positive NPC<\/td><\/tr><tr><td><strong>Peak Sales Forecast (China)<\/strong><\/td><td><strong>\u00a52.5\u20113.5\u202fbillion<\/strong> (~US$340\u2011480\u202fmillion) by 2032<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>40\u201150% of eligible HER3\u2011positive patients<\/td><\/tr><tr><td><strong>Competition<\/strong><\/td><td>First\u2011mover advantage; rivals (e.g., Daiichi\u2019s HER3 ADC) still in early development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Path:<\/strong> NDA acceptance triggers <strong>6\u2011month Priority Review<\/strong>; potential approval <strong>Q3\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>BMS Partnership:<\/strong> Global Phase\u202fIII program expansion funded by BMS; China approval will inform ex\u2011China regulatory strategy<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> U.S. Phase\u202fIII readout for other indications <strong>H2\u202f2026<\/strong>; potential for <strong>global filing<\/strong> in HER2\u2011negative breast cancer<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding iza\u2011bren\u2019s regulatory review timeline, commercial potential, and global development. Actual results may differ materially due to risks including NMPA approval outcomes, competitive dynamics, and BMS partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48858,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,16,38,25,857],"class_list":["post-48857","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-cancer","tag-market-approval-filings","tag-potential-first-in-class","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biokin&#039;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for iza-bren (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC, has been formally accepted by the National Medical Products Administration (NMPA) for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\/PD\u2011L1 therapy and at least two chemotherapy lines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48857\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biokin&#039;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for iza-bren (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC, has been formally accepted by the National Medical Products Administration (NMPA) for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\/PD\u2011L1 therapy and at least two chemotherapy lines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48857\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T12:00:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-24T12:00:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biokin&#8217;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC\",\"datePublished\":\"2025-11-24T12:00:21+00:00\",\"dateModified\":\"2025-11-24T12:00:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402-1.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Cancer\",\"Market approval filings\",\"Potential first-in-class\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48857#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48857\",\"name\":\"Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402-1.webp\",\"datePublished\":\"2025-11-24T12:00:21+00:00\",\"dateModified\":\"2025-11-24T12:00:22+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for iza-bren (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC, has been formally accepted by the National Medical Products Administration (NMPA) for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\\\/PD\u2011L1 therapy and at least two chemotherapy lines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48857\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48857#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biokin&#8217;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for iza-bren (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC, has been formally accepted by the National Medical Products Administration (NMPA) for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\/PD\u2011L1 therapy and at least two chemotherapy lines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48857","og_locale":"en_US","og_type":"article","og_title":"Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for iza-bren (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC, has been formally accepted by the National Medical Products Administration (NMPA) for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\/PD\u2011L1 therapy and at least two chemotherapy lines.","og_url":"https:\/\/flcube.com\/?p=48857","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T12:00:21+00:00","article_modified_time":"2025-11-24T12:00:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48857#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48857"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biokin&#8217;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC","datePublished":"2025-11-24T12:00:21+00:00","dateModified":"2025-11-24T12:00:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48857"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48857#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Cancer","Market approval filings","Potential first-in-class","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48857#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48857","url":"https:\/\/flcube.com\/?p=48857","name":"Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48857#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48857#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp","datePublished":"2025-11-24T12:00:21+00:00","dateModified":"2025-11-24T12:00:22+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its New Drug Application (NDA) for iza-bren (izalontamab brengitecan, BL\u2011B01D1), a first\u2011in\u2011class EGFR\u00d7HER3 bispecific ADC, has been formally accepted by the National Medical Products Administration (NMPA) for recurrent or metastatic nasopharyngeal carcinoma (NPC) patients who progressed after PD\u20111\/PD\u2011L1 therapy and at least two chemotherapy lines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48857#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48857"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48857#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp","width":1080,"height":608,"caption":"Biokin's iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48857#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biokin&#8217;s iza-bren NDA Accepted for Nasopharyngeal Carcinoma, Advancing Bispecific ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48857"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48857\/revisions"}],"predecessor-version":[{"id":48859,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48857\/revisions\/48859"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48858"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}